Results 181 to 190 of about 941,634 (294)

Phenotype‐specific immune profiles and outcomes in childhood autoimmune neutropenia: A 20‐year cohort study

British Journal of Haematology, EarlyView.
Summary Childhood autoimmune neutropenia (AIN) encompasses heterogeneous entities; phenotype‐specific immunological profiles and their relationship to infection outcomes remain incompletely defined. To characterise clinical, immunological and long‐term outcomes across distinct phenotypes of childhood AIN.
Ioanna Saougou, Chrysoula Kosmeri, Nikolaos Chaliasos, Irene Mavroudi, Charalampos Pontikoglou, Alexandros Makis   +5 more
wiley   +1 more source

Environmental triggers of autoimmune hepatitis: a clinical perspective from Yemeni patients. [PDF]

Front Immunol
Farie WQ, Bahaj SS, Al-Madhagi AK, Sher Ali S, Noman A, Alkassar WY.   +5 more
europepmc   +1 more source

Serum immunoglobulin G levels in patients with cirrhosis due to autoimmune hepatitis or other etiologies. [PDF]

Eur J Gastroenterol Hepatol
Su Y, Wang Q, Sun X, Zhao X, Zhao X, Jia J, Shan S.   +6 more
europepmc   +1 more source

INtraVESical immunoTherapy (INVEST) prior to radical cystectomy for bladder cancer: trial protocol

BJU International, EarlyView.
Background High‐risk non‐muscle‐invasive bladder cancer (HRNMIBC) has a variable prognosis, managed predominantly by local surgical resection and intravesical Bacillus Calmette–Guérin (BCG), or radical cystectomy (RC). Current treatments are poorly tolerated, have supply limitations and often fail to control the disease.
Ruby Lister‐Whelan, Ethan Senior, Jessica Kendall, Jamie B. Oughton, Fiona Collinson, Jon Griffin, Rachel Hubbard, Steven Kennish, Aidan Noon, Derek J. Rosario, Irbaz B. Riaz, Julie Telliez, James W. F. Catto, Syed A. Hussain   +13 more
wiley   +1 more source

COVID-19 vaccine-associated liver injury and autoimmune hepatitis: a case series. [PDF]

Ann Med Surg (Lond)
Mariyam N, Albitar MH, Shafqat A, FathAlrahman R, Fallatah HI, Abaalkhail F, Zahran AA, AlMahmoud A.   +7 more
europepmc   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Differentiating Autoimmune Hepatitis From Sulfasalazine Toxicity: The Value of Clinicopathologic Correlation. [PDF]

Cureus
Zoubi A, Bakhati B.
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Metabolomics in autoimmune hepatitis: progress and perspectives. [PDF]

Front Med (Lausanne)
Huang X, Mo W, Wang X.
europepmc   +1 more source

Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury

Modern Pathology, 2018
Y. Zen, M. Yeh
semanticscholar   +1 more source